Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Inflammation|January 28, 2005
Native versus recombinant high-mobility group B1 proteins: functional activity in vitroKlaus Zimmermann, Dirk Völkel, Sabrina Pable, et al.Oncotarget|September 17, 2016
Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancerAlexander Schinagl, Michael Thiele, Patrice Douillard, et al.Transfusion|December 3, 2003
Immunochemical detection of prion protein on dipsticks prepared with crystalline bacterial cell-surface layersDirk Völkel, Klaus Zimmermann, Andreas Breitwieser, et al.Blood|October 24, 2002
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)Barbara Plaimauer, Klaus Zimmermann, Dirk Völkel, et al.Molecular Cancer Therapeutics|April 27, 2013
Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivoFilza Hussain, Michael Freissmuth, Dirk Völkel, et al.British Journal of Clinical Pharmacology|March 25, 2020
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumoursDevalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, et al.The Journal of Biological Chemistry|January 13, 2012
Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIFRandolf J Kerschbaumer, Manfred Rieger, Dirk Völkel, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 26, 2015
Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory ConditionsMichael Thiele, Randolf J Kerschbaumer, Frederick W K Tam, et al.Pageof 1